[Treatment and secondary prevention of venous thromboembolism in cancer patients].

Autor: Shakaryants GA; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow., Budanova DA; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow., Lobastov KV; Federal State Budget Educational Institution of Higher Education N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation, Russian Federation, Moscow., Khabarova NV; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow., Kirichenko YY; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow., Belenkov YN; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University). Russian Federation, Moscow.
Jazyk: ruština
Zdroj: Kardiologiia [Kardiologiia] 2020 Mar 18; Vol. 60 (3), pp. 71-79. Date of Electronic Publication: 2020 Mar 18.
DOI: 10.18087/cardio.2020.3.n904
Abstrakt: Oncological patients are a high-risk group for venous thromboembolic complications. These complications significantly impair the outcome of antitumor treatment and take a leading place in the structure of mortality. Treatment of venous thromboembolic complications in oncological patients is a serious challenge. When selecting an anticoagulant, the physician should consider its efficacy and safety and possible drug interactions. Based on results of multiple studies presented in this article, physicians will be able to choose an optimum therapeutic tactics and secondary prevention of thromboembolic complications for this group of patients.
Databáze: MEDLINE
Externí odkaz: